{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:18:19Z","timestamp":1792700299696,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD20\/00199"],"award-info":[{"award-number":["CD20\/00199"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/00853"],"award-info":[{"award-number":["PI16\/00853"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["GLD18\/00151"],"award-info":[{"award-number":["GLD18\/00151"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cientificas","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background &amp; Aims<\/jats:title>\n                <jats:p>Advanced hepatic fibrosis is the main risk factor of liver-related morbidity and mortality in patients with chronic liver disease. In this study, we assessed the potential role of bone morphogenetic protein 8A (BMP8A) as a novel target involved in liver fibrosis progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Histological assessment and BMP8A expression were determined in different murine models of hepatic fibrosis. Furthermore, serum BMP8A was measured in mice with bile duct ligation (BDL), in 36 subjects with histologically normal liver (NL) and in 85 patients with biopsy-proven non-alcoholic steatohepatitis (NASH): 52 with non- or mild fibrosis (F0-F2) and 33 with advanced fibrosis (F3-F4). BMP8A expression and secretion was also determined in cultured human hepatocyte-derived (Huh7) and human hepatic stellate (LX2) cells stimulated with transforming growth factor \ua7b5 (TGF\ua7b5).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p><jats:italic>Bmp8a<\/jats:italic> mRNA levels were significantly upregulated in livers from fibrotic mice compared to control animals. Notably, serum BMP8A levels were also elevated in BDL mice. In addition, in vitro experiments showed increased expression and secretion to the culture supernatant of BMP8A in both Huh7 and LX2 cells treated with TGF\ua7b5. Noteworthy, we found that serum BMP8A levels were significantly higher in NASH patients with advanced fibrosis than in those with non- or mild fibrosis. In fact, the AUROC of circulating BMP8A concentrations to identify patients with advanced fibrosis (F3-F4) was 0.74 (<jats:italic>p<\/jats:italic>\u02c20.0001). Moreover, we developed an algorithm based on serum BMP8A levels that showed an AUROC of 0.818 (<jats:italic>p<\/jats:italic>\u02c20.0001) to predict advanced fibrosis in NASH patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study provides experimental and clinical evidence indicating that BMP8A is a novel molecular target linked to liver fibrosis and introduces an efficient algorithm based on serum BMP8A levels to screen patients at risk for advanced hepatic fibrosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40364-023-00489-2","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T20:24:19Z","timestamp":1682627059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis"],"prefix":"10.1186","volume":"11","author":[{"given":"Patricia","family":"Mara\u00f1\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephania C.","family":"Isaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Ernesto","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Gallego-Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Montero-Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Rodr\u00edguez","family":"de C\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ampuero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela M.","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Garc\u00eda-Monz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-2318","authenticated-orcid":false,"given":"\u00c1gueda","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"issue":"1","key":"489_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151\u201371.","journal-title":"J Hepatol"},{"issue":"5","key":"489_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cld.1061","volume":"17","author":"S Cheemerla","year":"2021","unstructured":"Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis (Hoboken). 2021;17(5):365\u201370.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"489_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","volume":"65","author":"M Parola","year":"2019","unstructured":"Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37\u201355.","journal-title":"Mol Aspects Med"},{"issue":"4","key":"489_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","volume":"9","author":"N Roehlen","year":"2020","unstructured":"Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875.","journal-title":"Cells"},{"issue":"3","key":"489_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1055\/s-2001-17550","volume":"21","author":"A Geerts","year":"2001","unstructured":"Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis. 2001;21(3):311\u201335.","journal-title":"Semin Liver Dis"},{"key":"489_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","volume":"11","author":"T Hardy","year":"2016","unstructured":"Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol. 2016;11:451\u201396.","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"489_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547\u201354.","journal-title":"Hepatology"},{"issue":"8","key":"489_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038\u201348.","journal-title":"Metabolism"},{"issue":"1124","key":"489_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1136\/postgradmedj-2018-136316","volume":"95","author":"E Jennison","year":"2019","unstructured":"Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95(1124):314\u201322.","journal-title":"Postgrad Med J"},{"key":"489_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-230X-11-91","volume":"11","author":"A Baranova","year":"2011","unstructured":"Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91.","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"489_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/gut.2010.216077","volume":"59","author":"S McPherson","year":"2010","unstructured":"McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265\u20139.","journal-title":"Gut"},{"issue":"3","key":"489_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","volume":"53","author":"ZH Lin","year":"2011","unstructured":"Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726\u201336.","journal-title":"Hepatology"},{"key":"489_CR13","unstructured":"Patricia M, Ernesto F-GC, Stephania CI, Esther R, Roc\u00edo G-D, Roc\u00edo M-V, et al. Bone morphogenetic protein 2 is a new molecular target linked to nonalcoholic fatty liver disease with potential value as non-invasive screening tool. MedRxiv. 2022."},{"issue":"5","key":"489_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3855\/jidc.4033","volume":"8","author":"N AktugDemir","year":"2014","unstructured":"AktugDemir N, Kolgelier S, Inkaya AC, Sumer S, Demir LS, Pehlivan FS, et al. Are bone morphogenetic protein-7 (BMP-7) serum levels correlated with development of hepatic fibrosis? J Infect Dev Ctries. 2014;8(5):605\u201310.","journal-title":"J Infect Dev Ctries"},{"issue":"12","key":"489_CR15","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1007\/s10620-007-9758-8","volume":"52","author":"F Tacke","year":"2007","unstructured":"Tacke F, G\u00e4bele E, Bataille F, Schwabe RF, Hellerbrand C, Klebl F, et al. Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci. 2007;52(12):3404\u201315.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"489_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1055\/s-0029-1216378","volume":"19","author":"M Chayanupatkul","year":"2009","unstructured":"Chayanupatkul M, Honsawek S, Vejchapipat P, Chongsrisawat V, Poovorawan Y. Elevated serum bone morphogenetic protein 7 levels and clinical outcome in children with biliary atresia. Eur J Pediatr Surg. 2009;19(4):246\u201350.","journal-title":"Eur J Pediatr Surg"},{"key":"489_CR17","doi-asserted-by":"publisher","first-page":"102794","DOI":"10.1016\/j.ebiom.2020.102794","volume":"56","author":"NE Owen","year":"2020","unstructured":"Owen NE, Alexander GJ, Sen S, Bunclark K, Polwarth G, Pepke-Zaba J, et al. Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis. EBioMedicine. 2020;56:102794.","journal-title":"EBioMedicine"},{"issue":"477","key":"489_CR18","doi-asserted-by":"publisher","first-page":"eaal1910","DOI":"10.1126\/scisignal.aal1910","volume":"10","author":"FJ Wu","year":"2017","unstructured":"Wu FJ, Lin TY, Sung LY, Chang WF, Wu PC, Luo CW. BMP8A sustains spermatogenesis by activating both SMAD1\/5\/8 and SMAD2\/3 in spermatogonia. Sci Signal. 2017;10(477):eaal1910.","journal-title":"Sci Signal"},{"key":"489_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.mce.2014.11.002","volume":"400","author":"D Chung","year":"2015","unstructured":"Chung D, Gao F, Jegga AG, Das SK. Estrogen mediated epithelial proliferation in the uterus is directed by stromal Fgf10 and Bmp8a. Mol Cell Endocrinol. 2015;400:48\u201360.","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"489_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2174\/1871530319666191018170022","volume":"20","author":"K Liu","year":"2020","unstructured":"Liu K, Gao M, Qin D, Wang H, Lu Q. Serous BMP8A has clinical significance in the ultrasonic diagnosis of thyroid cancer and promotes thyroid cancer cell progression. Endocr Metab Immune Disord Drug Targets. 2020;20(4):591\u20138.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"7","key":"489_CR21","doi-asserted-by":"publisher","first-page":"dmm038810","DOI":"10.1242\/dmm.038810","volume":"12","author":"A Villar-Lorenzo","year":"2019","unstructured":"Villar-Lorenzo A, Rada P, Rey E, Mara\u00f1\u00f3n P, Arroba AI, Santamar\u00eda B, et al. Insulin receptor substrate 2 (IRS2) deficiency delays liver fibrosis associated with cholestatic injury. Dis Model Mech. 2019;12(7):dmm038810.","journal-title":"Dis Model Mech"},{"issue":"6","key":"489_CR22","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u201321.","journal-title":"Hepatology"},{"issue":"9","key":"489_CR23","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467\u201374.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"489_CR24","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/cphy.c120035","volume":"3","author":"JE Puche","year":"2013","unstructured":"Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013;3(4):1473\u201392.","journal-title":"Compr Physiol"},{"issue":"37","key":"489_CR25","first-page":"5283","volume":"18","author":"L Zhang","year":"2012","unstructured":"Zhang L, Xu LM, Chen YW, Ni QW, Zhou M, Qu CY, et al. Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats. World J Gastroenterol. 2012;18(37):5283\u20138.","journal-title":"World J Gastroenterol"},{"issue":"30","key":"489_CR26","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.3748\/wjg.v25.i30.4222","volume":"25","author":"GL Zou","year":"2019","unstructured":"Zou GL, Zuo S, Lu S, Hu RH, Lu YY, Yang J, et al. Bone morphogenetic protein-7 represses hepatic stellate cell activation and liver fibrosis. World J Gastroenterol. 2019;25(30):4222\u201334.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"489_CR27","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/gutjnl-2014-306968","volume":"64","author":"S Arndt","year":"2015","unstructured":"Arndt S, Wacker E, Dorn C, Koch A, Saugspier M, Thasler WE, et al. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease. Gut. 2015;64(6):973\u201381.","journal-title":"Gut"},{"issue":"5","key":"489_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/cells8050457","volume":"8","author":"A Mahli","year":"2019","unstructured":"Mahli A, Seitz T, Beckr\u00f6ge T, Freese K, Thasler WE, Benkert M, et al. Bone morphogenetic protein-8B expression is induced in steatotic hepatocytes and promotes hepatic steatosis and inflammation in vitro. Cells. 2019;8(5):457.","journal-title":"Cells"},{"issue":"6","key":"489_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s42255-020-0214-9","volume":"2","author":"M Vacca","year":"2020","unstructured":"Vacca M, Leslie J, Virtue S, Lam BYH, Govaere O, Tiniakos D, et al. Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. Nat Metab. 2020;2(6):514\u201331.","journal-title":"Nat Metab"},{"issue":"9","key":"489_CR30","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1111\/liv.13879","volume":"38","author":"A Addante","year":"2018","unstructured":"Addante A, Roncero C, Almal\u00e9 L, Lazcanoiturburu N, Garc\u00eda-\u00c1lvaro M, Fern\u00e1ndez M, et al. Bone morphogenetic protein 9 as a key regulator of liver progenitor cells in DDC-induced cholestatic liver injury. Liver Int. 2018;38(9):1664\u201375.","journal-title":"Liver Int"},{"issue":"8","key":"489_CR31","first-page":"1626","volume":"7","author":"MM Zoheiry","year":"2015","unstructured":"Zoheiry MM, Hasan SA, El-Ahwany E, Nagy FM, Taleb HA, Nosseir M, et al. Serum Markers of Epithelial Mesenchymal Transition as Predictors of HCV-induced Liver Fibrosis. Cirr Hepatocellular Carc Elec Physician. 2015;7(8):1626\u201337.","journal-title":"Cirr Hepatocellular Carc Elec Physician"},{"key":"489_CR32","doi-asserted-by":"publisher","first-page":"8539","DOI":"10.2147\/IJGM.S385513","volume":"15","author":"J Hao","year":"2022","unstructured":"Hao J, Wang Y, Huo L, Sun T, Zhen Y, Gao Z, et al. Circulating bone morphogenetic protein-9 is decreased in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Gen Med. 2022;15:8539\u201346.","journal-title":"Int J Gen Med"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-023-00489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-023-00489-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-023-00489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:46:16Z","timestamp":1700394376000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-023-00489-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1186\/s40364-023-00489-2","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"3 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in agreement with the Declaration of Helsinki, and with local and national laws. The Human Ethics Committee of the Hospital Universitario Santa Cristina (reference, PI-688A) and Hospital Universitario Virgen del Roc\u00edo (reference, C.I. 0359-N-15) approved the study procedures, and all participants signed an informed written consent before inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}